58289-27-3

Usage

Uses

Used in Pharmaceutical Research:
6-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione is used as a research chemical for studying the effects and mechanisms of barbiturates on the central nervous system. Its use in this context aids in understanding the potential therapeutic applications and risks associated with this class of drugs.
Used in Controlled Substances Research:
Due to its potential for abuse and addiction, 6-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione is also used in research focused on developing strategies for the prevention and treatment of substance abuse, particularly related to barbiturate类药物.

Upstream product

• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 57-13-6 urea 
• 563-80-4 3-methyl-butan-2-one 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 28456-53-3 4-hydroxy-2-thio-6-isopropylpyrimidine 
• 28456-53-3 2,3-dihydro-6-isopropyl-2-thioxopyrimidin-4(1H)-one 

Downstream Products

• 58289-28-4 6-isopropyl-2,4-dihydroxy-5-nitropyrimidine 
• 89938-05-6 2,4-dichloro-6-(propan-2-yl)pyrimidine 
• 58289-29-5 2,4-dichloro-5-nitro-6-isopropylpyrimidine 
• 1373331-53-3 1-(7-chloro-5-(1-methylethyl)-1-phenyl-1H-pyrimido[4,5-e][1,3,4]thiadiazin-3-yl)-2-phenyldiazene 
• 58289-28-4 6-isopropyl-5-nitro-1H-pyrimidine-2,4-dione 
• 821795-61-3 3-benzhydryl-1-benzyl-6-isopropyl-1H-pyrimidine-2,4-dione 
• 821795-53-3 3-benzhydryl-6-isopropyl-1H-pyrimidine-2,4-dione 

Relevant academic research and scientific papers

Watson-Crick and Hoogsteen tri-base pairing: A co-crystal structure of a 2: Mplex of 6-isopropyluracil and adenine nucleobases

The formation of a tri-base pairing from free nucleobases is rare. A co-crystal structure obtained from an equimolar mixture of 6-isopropyluracil and adenine shows the formation of a tri-base pairing, where one molecule of free adenine is adhered to two molecules of the free pyrimidine nucleobase, involving both Watson-Crick and Hoogsteen base-pairing interactions. The Royal Society of Chemistry 2013.

DIHYDROPTERIDINONES I

The present invention relates to dihydropteridinones, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or it

DIHYDROPTERIDINONES I

The present invention relates to dihydropteridinones, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or it

AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE

The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.

JANUS KINASE INHIBITOR COMPOUNDS AND METHODS

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

Structure-Activity Relations. Part 12. Antibacterial Activity of a Series of 2,4-Diamino-6-substituted 5-(4-pyridylmethylamino)pyrimidines and 2,4-Diamino-5-(4-substituted benzylamino)pyrimidines.

A series of 6-substituted 2,4-diamino-5-(4-pyridylamino)pyrimidines and of 2,4-diamino-5-(4-substituted benzylamino)pyrimidines has been prepared.Their antibacterial activity towards L. casei, S. aureus and E. coli has been investigated.These activities have been successfully correlated by Hansch-type relations.Dependence on both lipophilicity and electronic (polar) factors has been found.The results are related to the structure and interactions with the receptor.